Last reviewed · How we verify
Administration of probiotics
Probiotics restore and maintain a healthy gut microbiota composition, enhancing intestinal barrier function and modulating immune responses.
Probiotics restore and maintain a healthy gut microbiota composition, enhancing intestinal barrier function and modulating immune responses. Used for Prevention or treatment of antibiotic-associated diarrhea, Inflammatory bowel disease management, Gastrointestinal health and microbiota restoration.
At a glance
| Generic name | Administration of probiotics |
|---|---|
| Sponsor | Hospital General Universitario Elche |
| Drug class | Probiotic |
| Modality | Biologic |
| Therapeutic area | Gastroenterology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Probiotics are live beneficial microorganisms that colonize the gastrointestinal tract, competing with pathogenic bacteria, producing short-chain fatty acids, and strengthening tight junctions in the intestinal epithelium. They also stimulate local and systemic immune responses through interaction with gut-associated lymphoid tissue (GALT), promoting regulatory T cell differentiation and reducing systemic inflammation.
Approved indications
- Prevention or treatment of antibiotic-associated diarrhea
- Inflammatory bowel disease management
- Gastrointestinal health and microbiota restoration
Common side effects
- Gastrointestinal bloating or gas
- Mild abdominal discomfort
- Transient diarrhea
Key clinical trials
- The Effects of a Probiotic Food Supplement in Hyperuricaemia (NA)
- Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis (NA)
- Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease (PHASE2)
- Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis (PHASE2)
- Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents (NA)
- Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients (PHASE2)
- Synbiotic to Attenuate Resorption of the Skeleton (NA)
- Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of probiotics CI brief — competitive landscape report
- Administration of probiotics updates RSS · CI watch RSS
- Hospital General Universitario Elche portfolio CI